<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan N Baer, MD, MACR</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Frederick B Vivino, MD, MS, MACR</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert I Fox, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3809334219"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sjögren's disease (SjD) is a chronic, multisystem autoimmune rheumatic disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement. In addition, a variety of systemic (so-called "extraglandular") manifestations may occur, including fatigue, musculoskeletal pain, rashes, and internal organ (eg, pulmonary, renal, hepatic, and neurologic) disease. There is also increased risk of non-Hodgkin B-cell lymphoma.</p><p>SjD occurs in a primary form, not associated with other autoimmune rheumatic diseases, and in an associated or overlap form, in which there is a concomitant second systemic autoimmune rheumatic disease such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis, and, less commonly, polymyositis/dermatomyositis.</p><p>The treatment of salivary gland enlargement, extraglandular manifestations affecting other organs and tissues, and constitutional symptoms will be reviewed here. An overview of the systemic treatment and prognosis of SjD, the clinical manifestations and diagnosis of SjD, and the treatment of dry eyes, dry mouth (including the use of muscarinic agonists such as <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> and <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a> as secretagogues), and other nonocular sicca symptoms, as well as neurologic manifestations of SjD, are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14921.html" rel="external">"Overview of the management and prognosis of Sjögren's disease"</a> and  <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">"Clinical manifestations of Sjögren's disease: Exocrine gland disease"</a> and  <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease"</a> and  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease"</a> and  <a class="medical medical_review" href="/z/d/html/14922.html" rel="external">"Treatment of dry eye in Sjögren’s disease: General principles and initial therapy"</a> and  <a class="medical medical_review" href="/z/d/html/14923.html" rel="external">"Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease"</a> and  <a class="medical medical_review" href="/z/d/html/120953.html" rel="external">"Neurologic manifestations of Sjögren's disease"</a>.)</p><p class="headingAnchor" id="H2579085059"><span class="h1">OVERVIEW OF MANAGEMENT</span><span class="headingEndMark"> — </span>An overview of the management and prognosis of Sjögren's disease (SjD) is presented separately (see  <a class="medical medical_review" href="/z/d/html/14921.html" rel="external">"Overview of the management and prognosis of Sjögren's disease"</a>). Key elements are reviewed briefly here together with the evidence supporting our approach to drug therapy. (See <a class="local">'Approach to drug therapy'</a> below and <a class="local">'Therapy for organ-based disease and constitutional symptoms'</a> below and <a class="local">'Therapeutic rationale and evidence overview'</a> below and <a class="local">'Efficacy of specific therapeutic agents'</a> below.)</p><p class="headingAnchor" id="H1170222398"><span class="h2">Treatment goals and principles</span><span class="headingEndMark"> — </span>The goals of therapy in patients with SjD are to ameliorate symptoms of dry eye and mouth, prevent complications of mucosal dryness (such as dental decay, corneal ulceration, or oral candidal infection), and detect and manage systemic manifestations and glandular and lymphoproliferative disease.</p><p>General principles that apply to the management of patients with SjD include care by a multidisciplinary team; the necessity of a thorough pretreatment evaluation; and treatment tailored to the individual patient with attention to the particular manifestations, severity of symptoms, and disease complications. These principles are described in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/14921.html" rel="external">"Overview of the management and prognosis of Sjögren's disease", section on 'Treatment goals and principles'</a>.)</p><p class="headingAnchor" id="H3104436206"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>The pretreatment evaluation should include the following elements, which are described in detail separately (see  <a class="medical medical_review" href="/z/d/html/14921.html" rel="external">"Overview of the management and prognosis of Sjögren's disease", section on 'Pretreatment evaluation'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Confirmation of the diagnosis of SjD and that the clinical manifestation targeted for treatment is due to SjD (see  <a class="medical medical_review" href="/z/d/html/14921.html" rel="external">"Overview of the management and prognosis of Sjögren's disease", section on 'Confirmation of the diagnosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of disease activity, based upon features of the history and physical examination, laboratory testing, and histopathologic findings (see  <a class="medical medical_review" href="/z/d/html/14921.html" rel="external">"Overview of the management and prognosis of Sjögren's disease", section on 'Assessment of disease activity and severity'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical determination of the disease subset, depending upon the presence or absence of glandular enlargement and the degree of systemic involvement (see  <a class="medical medical_review" href="/z/d/html/14921.html" rel="external">"Overview of the management and prognosis of Sjögren's disease", section on 'Determining disease subset'</a>)</p><p></p><p class="headingAnchor" id="H238068297"><span class="h2">Nonpharmacologic and preventive interventions</span><span class="headingEndMark"> — </span>All patients should receive nonpharmacologic and preventive interventions, including patient education and vaccinations. Several nonpharmacologic measures and other interventions are typically employed, as described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14921.html" rel="external">"Overview of the management and prognosis of Sjögren's disease", section on 'Nonpharmacologic and preventive interventions'</a>.)</p><p class="headingAnchor" id="H2514032628"><span class="h2">Approach to drug therapy</span><span class="headingEndMark"> — </span>Choice of therapy varies according to the organ manifestations and disease severity:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dry eye, dry mouth, and other sicca symptoms</strong> – SjD patients with sicca symptoms but without glandular enlargement or other organ involvement do not require systemic therapy other than secretagogues since ocular and oral symptoms generally do not improve with the use of systemic immunosuppressive agents. The treatment of dry eyes and of dry mouth and other nonocular sicca symptoms is described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14922.html" rel="external">"Treatment of dry eye in Sjögren’s disease: General principles and initial therapy"</a> and  <a class="medical medical_review" href="/z/d/html/14923.html" rel="external">"Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Organ-based disease and constitutional symptoms</strong> – The approach to extraglandular manifestations such as skin rashes, arthritis, vasculitis, and pulmonary and renal manifestations is generally similar to that used for systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA), depending upon the manifestation and its severity. Treatment of glandular lymphoproliferation and more severe extraglandular manifestations generally includes the use of glucocorticoids; antimalarials (<a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>); conventional nonbiologic disease-modifying antirheumatic drugs (DMARDs) such as <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, mycophenolic acid, and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>; and other potent agents, including the alkylating agent <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and the anti-CD20 antibody <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, which targets B cells. (See <a class="local">'Therapy for organ-based disease and constitutional symptoms'</a> below.)</p><p></p><p>There is only limited direct evidence to support this approach, which is based upon clinical practice guidelines, case series, limited clinical trial data for a few agents, our clinical experience, expert opinion, and indirect evidence from the use of these agents in other autoimmune rheumatic disorders. Recommendations for the management of SjD with systemic therapies have been published by the European Alliance of Associations for Rheumatology (EULAR; formerly known as European League Against Rheumatism) [<a href="#rid1">1</a>], the Sjögren's Foundation [<a href="#rid2">2</a>], British Society of Rheumatology [<a href="#rid3">3</a>], and Japan College of Rheumatology [<a href="#rid4">4</a>] as well as in a French National Diagnostic and Care Protocol [<a href="#rid5">5</a>]. (See <a class="local">'Therapeutic rationale and evidence overview'</a> below and <a class="local">'Efficacy of specific therapeutic agents'</a> below.)</p><p class="headingAnchor" id="H1828327342"><span class="h1">THERAPY FOR ORGAN-BASED DISEASE AND CONSTITUTIONAL SYMPTOMS</span><span class="headingEndMark"> — </span>In addition to the sicca symptoms, therapy may also require attention to glandular, lymphoproliferative, and systemic disease manifestations. The specific treatment depends upon the severity of involvement, the organs and tissues specifically affected, and the prior response to therapy.</p><p class="headingAnchor" id="H3816825852"><span class="h2">Salivary gland enlargement</span><span class="headingEndMark"> — </span>Enlargement of the major salivary glands may develop at any point during the disease course; may be unilateral, bilateral, acute and intermittent, or chronic; and regresses spontaneously in some patients.</p><p>We take the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute unilateral glandular swelling</strong> – Sudden painful unilateral salivary gland swelling with fever and erythema overlying the involved site should prompt concern for acute bacterial sialadenitis. Initial management includes the use of broad-spectrum antibiotics, hydration, and milking of the salivary glands to culture an infectious organism. Imaging by ultrasonography, computed tomography (CT), or magnetic resonance imaging (MRI) is used to rule out ductal obstruction and/or abscess formation. (See  <a class="medical medical_review" href="/z/d/html/13962.html" rel="external">"Suppurative parotitis in adults"</a>.)</p><p></p><p class="bulletIndent1">An episode of acute unilateral glandular swelling and discomfort without signs of infection is initially managed symptomatically with hot compresses, analgesics, milking of the affected salivary gland, and sucking on lemon drops. The swelling is often triggered by eating and can occur from ductal obstruction due to sialolithiasis or sialostenosis with mucus plugs. (See  <a class="medical medical_review" href="/z/d/html/6854.html" rel="external">"Salivary gland stones"</a>.)</p><p></p><p class="bulletIndent1">Recurrent episodes should be managed prophylactically with therapeutic doses of secretagogues (eg, <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a>, <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">cevimeline</a>) to increase salivary flow as well as regular milking of the salivary glands [<a href="#rid6">6,7</a>]. Sialoendoscopy may also be used to alleviate major salivary duct obstruction in refractory cases [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major salivary glandular enlargement</strong> – Intermittent subacute major salivary glandular enlargement most often affects the parotid glands and is caused by autoimmune sialadenitis. In the experience of the authors and other experts, this problem can be effectively managed with short courses of glucocorticoids (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 20 mg/day for one week followed by a gradual taper to finish a two-week course) [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">Chronic persistent salivary gland enlargement related to autoimmune sialadenitis is often difficult to manage, but patients can be reassured that the enlargement may sometimes resolve spontaneously over time. The enlargement is usually bilateral, although it may be asymmetric. It may be relapsing and remitting or persistent. Patients who report intermittent swelling often have chronically enlarged glands that do not cause other symptoms [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1">Systemic treatment is generally reserved for those patients with cosmetic concerns, glandular pain, or systemic involvement that would otherwise justify this therapeutic approach. We frequently use daily <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> or weekly <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> in doses equivalent to those used for rheumatoid arthritis (RA) to manage this problem (see  <a class="medical medical_review" href="/z/d/html/7491.html" rel="external">"Initial treatment of rheumatoid arthritis in adults", section on 'Initial therapy with methotrexate'</a> and  <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease", section on 'Routine eye examinations'</a>). <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> may be effective for autoimmune sialadenitis but is usually reserved for SjD patients with more serious organ involvement [<a href="#rid2">2,10</a>]. In a survey of North American pediatric rheumatologists, respondents reported prescribing hydroxychloroquine, corticosteroids, and methotrexate for the majority of pediatric SjD cases with recurrent parotitis. Rituximab, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, and <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">belimumab</a> were used in a minority of patients [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent major salivary gland swelling for more than 12 weeks</strong> – Major salivary gland swelling that persists for more than 12 weeks despite therapy should prompt concern for non-Hodgkin B-cell lymphoma, especially in circumstances where the involvement is unilateral and/or the gland feels indurated, nodular, or is associated with regional adenopathy [<a href="#rid12">12</a>]. Bilateral parotid gland enlargement, sometimes massive, is a less common presentation of salivary gland lymphoma.</p><p></p><p class="bulletIndent1">Such patients should undergo evaluation for glandular lymphoma or other neoplasm, which typically includes MRI or computed axial tomography of the neck and referral to an otolaryngologist or ultrasound radiologist for a fine-needle aspiration or ultrasound-guided core-needle biopsy [<a href="#rid13">13,14</a>]. In the evaluation of suspected lymphoma, it is important to collect specimens for flow cytometry (core-needle specimens and/or fine-needle aspirates) in addition to a core-needle biopsy for histopathologic analysis. Excisional biopsy may be required if the diagnosis remains indeterminate. An approach to treatment of lymphoma in SjD is described below. (See <a class="local">'Lymphoma'</a> below.)</p><p></p><p class="bulletIndent1">In SjD patients on chronic glucocorticoids, persistent parotid gland swelling may occur due to fatty infiltration, and management includes discontinuation of glucocorticoids in favor of other immunosuppressive therapies (if still needed) and weight-loss counseling.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lacrimal gland enlargement</strong> – Clinically overt enlargement of the lacrimal glands is uncommon in SjD. Its presence in a patient presenting for evaluation of possible SjD should prompt concern for alternative diagnoses, such as sarcoidosis and IgG4-related disease. In addition, lacrimal gland enlargement may be a presenting feature of lymphoma affecting the ocular adnexa in SjD.</p><p></p><p class="headingAnchor" id="H2721694687"><span class="h2">Musculoskeletal pain</span><span class="headingEndMark"> — </span>Treatment for musculoskeletal pain depends upon the cause of the symptoms, their severity, and the response to therapy; the spectrum of inflammatory musculoskeletal pain in SjD ranges from mild arthralgias and myalgias to frank synovitis and chronic pain. Additionally, age-related osteoarthritis and fibromyalgia may also contribute to musculoskeletal pain in SjD patients.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arthralgia and arthritis</strong> – Patients with mild joint symptoms, including those with mild arthritis and those with arthralgia and myalgia but lacking definite inflammatory synovitis, may be managed with nonsteroidal antiinflammatory drugs (NSAIDs) in antiinflammatory doses given daily or as needed depending upon symptom frequency.</p><p></p><p class="bulletIndent1">Patients with an inadequate response to NSAIDs after a one- to two-month trial or with moderate to severe symptoms usually require a traditional nonbiologic disease-modifying antirheumatic drug (DMARD) such as <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> or low-dose weekly <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, depending upon the severity of symptoms, in doses typically used for RA [<a href="#rid1">1-3,15-20</a>]. (See  <a class="medical medical_review" href="/z/d/html/7491.html" rel="external">"Initial treatment of rheumatoid arthritis in adults", section on 'Initial therapy with methotrexate'</a> and  <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease", section on 'Routine eye examinations'</a>.)</p><p></p><p class="bulletIndent1">Our approach is consistent with clinical practice guidelines for the use of DMARDs in inflammatory musculoskeletal pain in SjD that were issued in 2017 by a national consensus panel and that reaffirmed the use of <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> as initial therapy followed by <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and other agents, if needed. Choice of therapy also depends on the patient's other medical problems and careful consideration of the risk-benefit ratio [<a href="#rid2">2</a>]. These guidelines were based upon uncontrolled studies, similarity to the approach used to treat systemic lupus erythematosus (SLE) and mild RA, and the expert opinion of the consensus panel. Treatment-refractory cases, especially SjD patients with overlapping features of RA, may occasionally require biologic therapy with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or a tumor necrosis factor (TNF) alpha inhibitor [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibromyalgia</strong> – Up to 40 percent of SjD patients may also develop fibromyalgia as a comorbid illness and cause of musculoskeletal pain; thus, attention to sleep hygiene, treatment of nocturnal dryness, aerobics, and stretching exercises may alleviate symptoms. Management is very similar to fibromyalgia in patients without SjD, except that the use of medications with anticholinergic side effects is best avoided; these agents may exacerbate nighttime dryness and further disrupt sleep. The treatment of fibromyalgia is described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5627.html" rel="external">"Treatment of fibromyalgia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/118590.html" rel="external">"Overview of chronic widespread (centralized) pain in the rheumatic diseases", section on 'Systemic lupus erythematosus and Sjögren's disease'</a>.)</p><p></p><p>In SjD patients with musculoskeletal pain of uncertain etiology, a two-week course of low-dose <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (15 mg/day) followed by a rapid taper can sometimes help differentiate inflammatory from noninflammatory causes. A positive response may justify further treatment with immunosuppressive therapy.</p><p class="headingAnchor" id="H3686612117"><span class="h2">Fatigue</span><span class="headingEndMark"> — </span>As seen in other connective tissue disease patients, fatigue occurs frequently in SjD and can occasionally be severe and disabling. It is often multifactorial, and other related or coincidental causes of fatigue may contribute to patient symptoms. Thus, the initial approach to management includes a thorough evaluation to identify the etiology or etiologies of fatigue in the individual patient.</p><p>In patients with SjD, the major potential causes, in addition to the disease itself, include:</p><p class="bulletIndent1"><span class="glyph">●</span>A sleep disturbance (especially restless legs syndrome and obstructive sleep apnea) [<a href="#rid21">21,22</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Fibromyalgia</p><p class="bulletIndent1"><span class="glyph">●</span>Depression</p><p class="bulletIndent1"><span class="glyph">●</span>Hypothyroidism</p><p class="bulletIndent1"><span class="glyph">●</span>Dysautonomia</p><p class="bulletIndent1"><span class="glyph">●</span>Severe deficiencies of <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">vitamin B12</a> and/or vitamin D</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p></p><p>An approach to the evaluation of the adult patient with fatigue is presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2783.html" rel="external">"Approach to the adult patient with fatigue"</a>.)</p><p>In patients with fatigue that is largely related to the SjD itself, we suggest a low-impact aerobic exercise program and various psychoeducational interventions (eg, cognitive behavioral therapy, mindfulness, stress reduction, motivational counseling) as first-line therapy for all patients. In patients with fatigue refractory to exercise and other lifestyle changes, we use <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> in a fashion similar to the approach utilized for SLE. (See  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Treatment of specific SLE manifestations'</a>.)</p><p>This approach is consistent with clinical practice guidelines for management of fatigue in SjD that have been developed by a national consensus panel in the United States, which strongly recommended aerobic exercise as first-line therapy for all patients [<a href="#rid2">2</a>]. The efficacy of nonpharmacologic interventions is supported by a systematic review that informed the 2023 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases [<a href="#rid23">23</a>]. The choice of other therapies is customized for every individual depending on the results of the evaluation.</p><p>For those patients with disabling fatigue refractory to <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, we sometimes use a positive response to a two-week course of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 15 mg/day as evidence to support treatment with additional immunosuppressive therapy, including chronic low-dose or alternate-day prednisone, conventional DMARDs, or biologic agents such as <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (see  <a class="medical medical_review" href="/z/d/html/14921.html" rel="external">"Overview of the management and prognosis of Sjögren's disease"</a>). Given the potential hazards of immunosuppressive therapy, these agents should only be continued in patients who demonstrate significant improvement of fatigue following treatment over a six-month trial period.</p><p class="headingAnchor" id="H1438408064"><span class="h2">Cutaneous manifestations</span><span class="headingEndMark"> — </span>Several different skin manifestations may occur in patients with SjD and require distinct management approaches:</p><p class="headingAnchor" id="H1077713833"><span class="h3">Pruritus</span><span class="headingEndMark"> — </span>Pruritus in SjD is common and often exacerbated by xeroderma [<a href="#rid24">24</a>]. It may be treated by the use of oilated soaps and shampoos, less frequent bathing, the application of body oils or skin lotions (eg, 12% <a class="drug drug_general" data-topicid="10073" href="/z/d/drug information/10073.html" rel="external">ammonium lactate</a> lotion) to wet skin immediately after bathing, and, whenever possible, the discontinuation of medications with anticholinergic effects (see  <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">"Pruritus: Therapies for generalized pruritus", section on 'Xerosis (dry skin)'</a>). Pruritus can be an occasional symptom of a small-fiber sensory neuropathy in SjD.</p><p>In the authors' experience, dermatographic urticaria also occurs in SjD, can exacerbate chronic pruritus, and can cause migratory cutaneous stinging and burning sensations that mimic neuropathic pain. Symptoms are frequently exacerbated by exposure to tartrazine dyes (ie, Food, Drug, and Cosmetic [FD&amp;C] yellow #5) [<a href="#rid25">25,26</a>]. Treatment with a tartrazine-free and salicylate-free diet, dye-free <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">fexofenadine</a> (60 mg twice/day), and a dye-free <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">famotidine</a> (20 mg twice daily) is effective. Short courses of low-dose oral glucocorticoids (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 15 mg/day or less for two to three months) may be useful in treatment-resistant cases. (See  <a class="medical medical_review" href="/z/d/html/8109.html" rel="external">"Physical (inducible) forms of urticaria", section on 'Overview of treatment approach'</a>.)</p><p>In patients with pruritus refractory to these treatments, screening for primary biliary cholangitis (primary biliary cirrhosis) is indicated. (See  <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis"</a>.)</p><p class="headingAnchor" id="H3106595702"><span class="h3">Annular erythema</span><span class="headingEndMark"> — </span>Annular erythema may occur in SjD (especially in patients with anti-SSA/Ro antibodies) and resembles subacute cutaneous lupus. This cutaneous eruption is characterized by annular polycyclic lesions with a wide elevated border and central pallor [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease", section on 'Annular erythema'</a>.)</p><p>Initial treatment options include topical steroids, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, or <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a>; in patients with more extensive and severe skin involvement, treatment may require oral glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 5 to 30 mg/day) [<a href="#rid28">28-30</a>] in combination with <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>.</p><p>For recurrent skin lesions, we use systemic therapies that have benefit in cutaneous lupus, including <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (with or without concomitant quinacrine) or low-dose weekly <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. SjD patients with treatment-refractory skin lesions should be referred to a dermatologist for skin biopsy, confirmation of the diagnosis, and consideration of other therapies. Additional options include low-dose <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> or its analogs, and <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> [<a href="#rid30">30,31</a>]. (See  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/13772.html" rel="external">"Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus"</a> and  <a class="medical medical_review" href="/z/d/html/13775.html" rel="external">"Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to antimalarial therapy"</a>.)</p><p class="headingAnchor" id="H4262696013"><span class="h3">Cutaneous vasculitis</span><span class="headingEndMark"> — </span>Cutaneous vasculitis in SjD, which presents as palpable or nonpalpable purpura, erythematous macules or papules, urticarial-like lesions, cutaneous ulcers, and, rarely, digital necrosis [<a href="#rid32">32</a>], is most often caused by leukocytoclastic vasculitis and may occur with or without cryoglobulinemia. (See  <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease", section on 'Cutaneous vasculitis'</a>.)</p><p>SjD patients with cutaneous vasculitis should be evaluated for other organ involvement, especially that of the kidneys, joints, and peripheral nervous system; such testing should include serum cryoglobulins, complement levels, and testing for hepatitis C (see  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease", section on 'Diagnostic testing'</a>). The presence or absence of serum cryoglobulins in an SjD patient with palpable purpura serves to differentiate two broad categories of cutaneous vasculitis with prognostic implications [<a href="#rid33">33</a>].</p><p>Patients with recurrent flat, petechial or small purpuric lesions on the lower extremities (often termed "benign hypergammaglobulinemic purpura of Waldenström") [<a href="#rid34">34,35</a>] (see  <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease", section on 'Cutaneous vasculitis'</a>) can be effectively managed with compression stockings, avoidance of prolonged standing, and <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> [<a href="#rid36">36</a>] (see  <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease"</a>). In the absence of cryoglobulins, this form of vasculitis is generally not associated with systemic manifestations of vasculitis, such as neuropathy and nephritis [<a href="#rid33">33</a>]. <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> 0.6 mg twice/day [<a href="#rid37">37</a>] may also be effective in suppressing the lesions. Patients who are refractory to standard therapies or have more severe symptoms may require a two- to three-week course of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 15 to 30 mg/day followed by rapid taper.</p><p>Individuals with treatment-refractory attacks, or whose biopsies demonstrate involvement of medium-sized muscular arteries, should also be evaluated for the presence of cryoglobulins. They are treated with oral DMARDs (eg, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> [<a href="#rid38">38</a>], <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>) or intravenous (IV) <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> at doses typically used to manage RA [<a href="#rid2">2,34</a>] or with longer courses of glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> &lt;30 mg/day). (See  <a class="medical medical_review" href="/z/d/html/7491.html" rel="external">"Initial treatment of rheumatoid arthritis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7477.html" rel="external">"Alternatives to methotrexate for the initial treatment of rheumatoid arthritis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>.)</p><p>Patients with severe cutaneous ulceration, digital necrosis, or life-threatening organ involvement may require treatment with plasma exchange, high-dose oral or IV pulse glucocorticoids, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid2">2,39</a>].</p><p>Cryoglobulinemic vasculitis warrants special consideration and is treated according to the severity of the skin disease and extent/severity of internal organ involvement (eg, peripheral neuropathy, glomerulonephritis, etc). It is often associated with underlying or evolving lymphoma. Additionally, hepatitis C must be excluded since its presence would mandate consideration of antiviral therapy. (See  <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease", section on 'Cutaneous vasculitis'</a> and  <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease", section on 'Vasculitis'</a> and  <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease", section on 'Cryoglobulins'</a> and  <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease", section on 'Lymphoma'</a> and  <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">"Mixed cryoglobulinemia syndrome: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H3891435815"><span class="h2">Raynaud phenomenon</span><span class="headingEndMark"> — </span>Raynaud phenomenon is common, especially in the subset of patients with anticentromere antibodies, and is treated as it is in other rheumatic diseases. (See  <a class="medical medical_review" href="/z/d/html/7540.html" rel="external">"Treatment of Raynaud phenomenon: Initial management"</a>.)</p><p class="headingAnchor" id="H1714918178"><span class="h2">Cardiopulmonary manifestations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interstitial lung disease</strong> – Interstitial lung disease (most commonly nonspecific interstitial pneumonitis) occurs in approximately 10 percent of SjD patients and is often more successfully treated with corticosteroids than lung disease in RA and systemic sclerosis. In the 2021 Sjogren’s Foundation consensus guidelines for the evaluation and management of pulmonary disease in SjD, it was recommended that all patients be screened for pulmonary disease with a baseline chest radiograph and pulmonary function testing for lung volumes, spirometry, and bronchodilators [<a href="#rid40">40</a>]. Symptomatic patients should also undergo high-resolution computerized axial tomography of the chest. Comprehensive management of interstitial pneumonitis and pulmonary manifestations of SjD is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15921.html" rel="external">"Interstitial lung disease associated with Sjögren's disease: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Xerotrachea</strong> – Xerotrachea related to exocrine gland dysfunction may also contribute to the patient symptoms (eg, cough) and may, in the authors' experience, be alleviated with therapeutic doses of secretagogues or <a class="drug drug_general" data-topicid="8503" href="/z/d/drug information/8503.html" rel="external">guaifenesin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary hypertension</strong> – Pulmonary hypertension is treated according to paradigms established for other connective tissue diseases, such as SLE and systemic sclerosis [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a> and  <a class="medical medical_review" href="/z/d/html/8256.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">"Pulmonary manifestations of systemic lupus erythematosus in adults", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pleuropericarditis</strong> – Pleuritis and pericarditis are rare in SjD and should always prompt evaluation for SLE, an overlap syndrome, or other causes. Treatment approaches parallel those used in SLE. Depending upon the specific problem and severity, useful agents to treat one or both of these manifestations may include NSAIDs, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> 0.6 mg twice/day, glucocorticoids, or <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>. (See  <a class="medical medical_review" href="/z/d/html/4680.html" rel="external">"Non-coronary cardiac manifestations of systemic lupus erythematosus in adults", section on 'Pericardial disease'</a> and  <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">"Pulmonary manifestations of systemic lupus erythematosus in adults"</a>.)</p><p></p><p class="headingAnchor" id="H450592696"><span class="h2">Kidney</span><span class="headingEndMark"> — </span>The principal types of renal involvement are interstitial nephritis (IN) with renal tubular acidosis (RTA) and, less commonly, membranoproliferative glomerulonephritis (GN) [<a href="#rid27">27</a>]. The renal manifestations of SjD and their management are described separately. (See  <a class="medical medical_review" href="/z/d/html/7187.html" rel="external">"Kidney disease in primary Sjögren's disease"</a>.)</p><p>Other renal problems include thrombotic glomerulopathy as in the antiphospholipid syndrome (APS) (see  <a class="medical medical_review" href="/z/d/html/3073.html" rel="external">"Antiphospholipid syndrome and the kidney"</a> and  <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>). The treatment of APS-causing thrombotic glomerulopathy in SjD is the same as for patients with SLE. (See  <a class="medical medical_review" href="/z/d/html/3073.html" rel="external">"Antiphospholipid syndrome and the kidney", section on 'Kidney disease in APS associated with systemic lupus erythematosus'</a> and  <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>.)</p><p class="headingAnchor" id="H4046613271"><span class="h2">Gastrointestinal</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastroesophageal reflux</strong> – Many patients have symptoms of gastroesophageal reflux disease (GERD), with resultant laryngotracheal irritation. Treatment of these problems with proton pump inhibitors, H2 blockers, promotility agents, and dietary modification is similar to that for patients with GERD without SjD. The use of secretagogues to stimulate saliva flow and neutralize stomach acid may also be beneficial. (See  <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/14923.html" rel="external">"Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease", section on 'Inadequate response to salivary stimulation and substitutes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dysphagia</strong> – Dysphagia may occur due to dryness, reflux, esophageal dysmotility, or, less commonly, the presence of a Zenker's diverticulum or esophageal web. Upper endoscopy and/or a <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> swallow with video esophagogram will usually reveal the cause and facilitate treatment. Use of secretagogues may alleviate dysphagia related to dryness. (See  <a class="medical medical_review" href="/z/d/html/2241.html" rel="external">"Approach to the evaluation of dysphagia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/14923.html" rel="external">"Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease", section on 'Inadequate response to salivary stimulation and substitutes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrophic gastritis</strong> – Atrophic gastritis and associated pernicious anemia may require parenteral or sublingual <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">vitamin B12</a> supplementation [<a href="#rid42">42</a>]. We exclude <em>Helicobacter pylori </em>as a potential cause of the gastritis in these patients. (See  <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease", section on 'Gastrointestinal tract'</a> and  <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Celiac disease</strong> – The incidence of celiac disease may be higher in SjD than in the general population [<a href="#rid43">43</a>], and treatment for this problem may prevent neurologic manifestations that mimic SjD, including ataxic peripheral neuropathies and nutritional deficiencies. (See  <a class="medical medical_review" href="/z/d/html/4777.html" rel="external">"Management of celiac disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary biliary cholangitis and autoimmune hepatitis</strong> – Primary biliary cholangitis (primary biliary cirrhosis) and chronic active autoimmune hepatitis may be associated with SjD and are treated as detailed separately [<a href="#rid44">44,45</a>]. (See  <a class="medical medical_review" href="/z/d/html/3623.html" rel="external">"Overview of the management of primary biliary cholangitis"</a> and  <a class="medical medical_review" href="/z/d/html/3659.html" rel="external">"Management of autoimmune hepatitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diarrhea</strong> – Diarrhea in the SjD patient may occur as a side effect of secretagogue use, small intestinal bacterial overgrowth syndrome (SIBO) [<a href="#rid46">46</a>], concomitant celiac disease [<a href="#rid43">43</a>], or lymphocytic colitis [<a href="#rid47">47</a>]. Treatment depends upon the specific diagnosis and is the same as in patients without SjD. (See  <a class="medical medical_review" href="/z/d/html/4777.html" rel="external">"Management of celiac disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings"</a> and  <a class="medical medical_review" href="/z/d/html/2591.html" rel="external">"Approach to the adult with chronic diarrhea in resource-abundant settings"</a>.)</p><p></p><p class="headingAnchor" id="H4029047105"><span class="h2">Neurologic manifestations</span><span class="headingEndMark"> — </span>Management of the neurologic manifestations of SjD varies depending upon the particular form of neurologic involvement and is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/120953.html" rel="external">"Neurologic manifestations of Sjögren's disease"</a>.)</p><p class="headingAnchor" id="H1829168170"><span class="h2">Hematologic</span><span class="headingEndMark"> — </span>Hematologic manifestations are common in SjD and include cytopenias, monoclonal gammopathies, and non-Hodgkin B-cell lymphoma [<a href="#rid48">48</a>]. (See <a class="local">'Cytopenias'</a> below and <a class="local">'Monoclonal gammopathy'</a> below and <a class="local">'Lymphoma'</a> below.).</p><p class="headingAnchor" id="H3824672348"><span class="h3">Cytopenias</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukopenia</strong> – The majority of patients with leukopenia, including those with neutropenia, are asymptomatic and do not require specific therapy. The use of antibiotics is reserved for those with infections. In patients with severe infections or those requiring surgery, treatment may include glucocorticoids, intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), or granulocyte-stimulating factors [<a href="#rid49">49,50</a>]. We use glucocorticoids with or without IVIG before granulocyte-stimulating factor. Case reports highlight the potential benefit of <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil [<a href="#rid51">51</a>], but not <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid50">50</a>], as chronic therapy for agranulocytosis. T-cell large granular lymphocytic leukemia is a rare cause of neutropenia in SjD and has a specific treatment protocol [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/z/d/html/4536.html" rel="external">"Treatment of large granular lymphocyte leukemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia</strong> – Immune thrombocytopenia in SjD is often mild and clinically silent. Severe cases are treated as in other systemic rheumatic diseases, with glucocorticoids and <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. (See  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia</strong> – The most common form is a mild normochromic normocytic anemia of chronic inflammation, which does not require specific treatment. Other forms include hemolytic anemia, pure red cell aplasia, and pernicious anemia. Treatment should be tailored to the cause and is the same as it would be for a patient without SjD. (See  <a class="medical medical_review" href="/z/d/html/7120.html" rel="external">"Acquired pure red cell aplasia in adults", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a> and  <a class="medical medical_review" href="/z/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Initial management'</a>.)</p><p></p><p class="headingAnchor" id="H2163044728"><span class="h3">Monoclonal gammopathy</span><span class="headingEndMark"> — </span>Monoclonal proteins are present in up to 20 percent of patients, and occasionally herald the onset of a plasma cell dyscrasia or lymphoma. We evaluate these according to guidelines recommended for monoclonal gammopathy of undetermined significance (see  <a class="medical medical_review" href="/z/d/html/6652.html" rel="external">"Diagnosis of monoclonal gammopathy of undetermined significance"</a>) and monitor relevant laboratory studies (eg, serum-free light chain ratio, immunoglobulin levels) on an annual basis unless specific symptoms arise suggesting the development of a hematologic malignancy. In addition, monoclonal proteins may be an indication of cryoglobulinemia [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H327260760"><span class="h3">Lymphoma</span><span class="headingEndMark"> — </span>The treatment of lymphomas seen in patients with SjD [<a href="#rid54">54</a>], including marginal zone lymphomas (MZL; both extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue [MALT lymphoma] and nodal MZL) and large B-cell lymphoma, uses the same regimens as in patients without SjD. (See  <a class="medical medical_review" href="/z/d/html/4710.html" rel="external">"Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)"</a> and  <a class="medical medical_review" href="/z/d/html/16228.html" rel="external">"Initial treatment of limited stage diffuse large B cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma"</a>.)</p><p>However, the management of MALT lymphoma in SjD involves unique considerations, including its usual noninfectious etiology, frequent occurrence with SjD systemic disease manifestations, and potential for specific therapy-related complications. Approaches to the management of MALT lymphoma of the parotid gland in SjD have been outlined by two sets of investigators [<a href="#rid55">55,56</a>]. The initial staging evaluation should include MRI or CT of the head and neck to define the extent of salivary gland involvement and the presence of enlarged regional lymph nodes. The need for CT of the chest and abdomen, bone marrow biopsy, and upper gastrointestinal endoscopy is debated and depends on the patient's clinical presentation. (See  <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"</a>.)</p><p>For patients with localized MALT and mild extraglandular disease, a strategy of watchful waiting may be adopted. This approach may also apply to some asymptomatic patients with disseminated disease but low SjD activity. Indications for treatment include cosmetic concerns or pain associated with the parotid enlargement. We do not use low-dose involved field radiotherapy to treat enlarged salivary glands, because it has the potential to aggravate xerostomia if a significant amount of salivary gland tissue is included in the radiation field.</p><p>The primary indications for treatment of MALT lymphoma are disseminated (bone marrow or nodal) disease and adverse prognostic markers (eg, International Prognostic Index score&gt;1 (see  <a class="medical medical_review" href="/z/d/html/83821.html" rel="external">"Prognosis of diffuse large B cell lymphoma"</a>)) and those with severe extraglandular SjD disease activity. The favored treatment regimens include <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, either alone or with additional chemotherapy.</p><p class="headingAnchor" id="H80959970"><span class="h1">THERAPEUTIC RATIONALE AND EVIDENCE OVERVIEW</span><span class="headingEndMark"> — </span>Our approach is based upon case series, clinical trial data, our clinical experience, and expert opinion, including consensus guidelines [<a href="#rid1">1-5,15,16,40,57-62</a>]. It is also supported by indirect evidence from the use of these agents in other autoimmune rheumatic disorders, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), which sometimes overlap with Sjögren's disease (SjD). (See  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a>.)</p><p>There is inadequate evidence of efficacy and safety to justify use of systemic immunosuppressants to treat sicca symptoms alone or use of immunosuppressive drugs or biologic agents as long-term disease suppressants. The use of these agents in patients with SjD is thus primarily supported by indirect evidence, including their benefit for clinical manifestations of SLE or features of SjD in patients with RA. Clinical trials assessing the efficacy of therapeutic agents for cardinal disease manifestations of SjD, such as dryness, pain, and fatigue, have been severely limited by the absence of ideal primary endpoints, disease heterogeneity, the challenge of distinguishing between disease activity and permanent damage, and uncertainty as to the best inclusion criteria and trial duration [<a href="#rid63">63</a>]. Accordingly, randomized trials of most agents studied have yielded negative results, and efforts to define better clinical trial endpoints and outcome measures are ongoing [<a href="#rid64">64-67</a>]. Thus, none of the traditional disease-modifying antirheumatic drugs (DMARDs) or biologic agents used for treatment of SjD have been approved by the US Food and Drug Administration (FDA) specifically for use in SjD.</p><p class="headingAnchor" id="H2606837497"><span class="h1">EFFICACY OF SPECIFIC THERAPEUTIC AGENTS</span></p><p class="headingAnchor" id="H282396278"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>There have been no large trials addressing the potential benefit of glucocorticoids for the glandular manifestations of Sjögren’s disease (SjD). In a small randomized, controlled trial, neither <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (30 mg every other day) nor <a class="drug drug_general" data-topicid="9781" href="/z/d/drug information/9781.html" rel="external">piroxicam</a> (20 mg/day) treatment, compared with placebo, resulted in significant improvement of salivary and lacrimal gland function or salivary gland histopathology after six months [<a href="#rid68">68</a>]. By contrast, in an uncontrolled open-label trial involving 20 SjD patients, <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> therapy (mean starting dose of 15 mg/day, tapering to 5 to 7.5 mg/day after 12 months and 5 mg/day after 30 months) was associated with a significant increase in whole saliva flow compared with baseline starting at one month and sustained to the end of the trial at 48 months [<a href="#rid69">69</a>]. The authors use brief courses of glucocorticoids for acute episodes of noninfectious sialadenitis but have not observed any significant benefit from prolonged glucocorticoids for treatment of sicca.</p><p>Long-term use of glucocorticoids in SjD is also tempered by concern for potential side effects, including osteoporosis, hyperglycemia, weight gain, agitation, and increased risk of infections, as in rheumatoid arthritis (RA) and other diseases (see  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>). In SjD patients, an increased risk of oral candidiasis and acceleration of dental decay further limit the prolonged use of glucocorticoids at higher dose [<a href="#rid70">70</a>].</p><p>Glucocorticoids are sometimes used to treat systemic manifestations of SjD in a manner similar to that in other systemic rheumatic and autoimmune diseases [<a href="#rid15">15</a>]. In an analysis of 1120 Spanish patients with primary SjD, low-dose glucocorticoids (equivalent to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> ≤20 mg/day) were used for this purpose in 19 percent of such patients [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H2366160827"><span class="h2">Conventional immunosuppressive drugs and nonbiologic DMARDs</span><span class="headingEndMark"> — </span>Disease-modifying antirheumatic drugs (DMARDs) are primarily used to treat specific organ manifestations in a manner similar to systemic lupus erythematosus (SLE), particularly to taper or replace glucocorticoids. Their utility for the treatment of glandular manifestations of the disease has been disappointing. Briefly, clinical trials of these agents have included the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> – Therapy with hydroxychloroquine is largely based upon its efficacy in SLE [<a href="#rid17">17,18</a>]. Small, open-label trials and observational studies have found improvement in arthralgias, myalgias, acute phase reactants, and hypergammaglobulinemia [<a href="#rid19">19,72-74</a>]. In a three-year longitudinal analysis of the Korean Initiative SS cohort (KISS) of 256 patients, the use of hydroxychloroquine was associated with a significant lowering of serum IgG levels and less solid organ damage [<a href="#rid75">75</a>]. However, a 24-week randomized trial involving 120 patients did not reach its primary endpoint of 30 percent or greater reduction in two of three numeric analog scales evaluating fatigue, pain, or dryness [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> – A one-year pilot study of methotrexate (0.2 mg/kg weekly) in 17 patients with primary SjD showed improvement in dry mouth and eye symptoms, arthralgias, arthritis, and the frequency of parotid gland enlargement and purpura. However, no improvement in objective parameters of dry eyes and dry mouth was observed [<a href="#rid77">77</a>]. A retrospective case review of articular manifestations in a large French cohort also reported benefit in 11 of 12 SjD patients treated with methotrexate for musculoskeletal pain [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> – In a randomized trial of low-dose azathioprine (1 mg/kg/day) in 25 patients with primary SjD, there was no significant change in disease activity over a period of six months [<a href="#rid78">78</a>]. However, azathioprine at higher doses is commonly used in the management of specific extraglandular involvement, such as interstitial pneumonitis, myelopathy, and chronic active autoimmune hepatitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">Leflunomide</a> – In an open-label pilot study, leflunomide (20 mg/day) provided only modest benefits for 15 patients with early and active primary SjD [<a href="#rid79">79</a>]. However, there was notable improvement in leukocytoclastic vasculitis in three patients. The treatment was associated with the development of lupus-like skin lesions in five patients. In a study of RA, leflunomide therapy was associated with worsening of eye dryness in a group of 45 patients with RA with secondary SjD as compared with 30 without secondary SjD [<a href="#rid38">38</a>]. A small, controlled, randomized 24-week trial of combination therapy with leflunomide (20 mg/day) and <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (400 mg/day) showed significant clinical efficacy (improvement of European Alliance of Associations for Rheumatology [EULAR] Sjögren's Syndrome Disease Activity Index [ESSDAI] scores versus baseline) when compared with placebo alone in a study involving 29 patients; these results need verification in a larger study [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> – In an open-label pilot study of 11 patients with primary SjD, mycophenolate in doses up to 1440 mg/day for six months did not improve objective measures of ocular or oral dryness but did lead to significant reductions in hypergammaglobulinemia and rheumatoid factor (RF) and an increase in complement and white blood count levels [<a href="#rid81">81</a>]. A small retrospective case series from France reported benefit or stabilization of SjD-related sensory ganglionopathy in 11 of 12 SjD patients following treatment with mycophenolate mofetil and glucocorticoids or mycophenolate alone [<a href="#rid82">82</a>]. A case report documented thatthis medication was also effective in treating refractory agranulocytosis in a patient with primary SjD [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> – In a randomized trial, cyclosporine (5 mg/kg/day) resulted in symptomatic improvement of dry mouth at six months, compared with placebo, but no change in dry eye symptoms or objective parameters of ocular and oral dryness [<a href="#rid83">83</a>]. In an open-label extension, labial gland histopathology worsened at 12 months in cyclosporine-treated patients [<a href="#rid84">84</a>]. In an open-label trial of low dose cyclosporine (2mg/kg/day) in 30 SjD patients with active articular involvement, there was a significant reduction in tender and swollen joints after 16 weeks of treatment [<a href="#rid85">85</a>].</p><p></p><p class="headingAnchor" id="H646701967"><span class="h2">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a>, a chimeric monoclonal antibody directed against the CD20 cell surface marker on B cells and their precursors, has been studied extensively as a treatment option [<a href="#rid86">86</a>]. The findings have been variable, as illustrated by a number of reports, including randomized trials, open-label studies, and retrospective case reports and series [<a href="#rid87">87-91</a>]. In the two largest randomized trials of rituximab, the primary outcome measures, reduction of patient-reported dryness and fatigue, were not met, although the suitability of these outcome measures has been questioned [<a href="#rid89">89,92,93</a>]. The drug has been reported to be of benefit for specific extraglandular manifestations in retrospective case series and registry analyses.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Randomized trials</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Tolerance and Efficacy of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> in Primary Sjögren's Syndrome (TEARS) trial was a multicenter 24-week trial of rituximab versus placebo for dryness and fatigue (given in two infusions over two weeks) [<a href="#rid89">89</a>]. It enrolled 120 SjD patients and demonstrated some symptomatic improvement at weeks 6 and/or 16 in disease activity, fatigue, and dryness. However, the study failed to document a statistically significant difference in the primary study endpoint at six months, defined as at least 30 mm improvement in two of four visual analog scales for global disease, pain, fatigue, and dryness. Limitations of the study included low disease activity at baseline and a primary outcome that may have been insensitive to detecting clinically important changes [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A study of anti-B-cell therapy in patients with primary SjD, called the TRACTISS trial, was a multicenter 48-week trial of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> versus placebo for fatigue and dryness (given as infusions at 0, 2, 24, and 26 weeks). Among 133 randomized patients, there were no significant differences in any outcome measures except unstimulated salivary flow, where placebo-treated patients showed a modest decline in flow relative to rituximab-treated patients [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a randomized trial, 30 patients with SjD and measurable baseline salivary flow (ie, stimulated salivary flow rate ≥0.15 mL/minute) were assigned to receive <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (20 patients) or placebo (10 patients) [<a href="#rid91">91</a>]. All patients received intravenous (IV) <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> before infusion and a tapering course of oral <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> afterward. There was significant improvement in salivary secretion and visual analog scales for oral and ocular dryness in the rituximab treatment group. These benefits were observed between 12 and 36 weeks after treatment but not at the 48-week endpoint of the trial.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a randomized trial involving 17 patients, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> did not reduce fatigue, the primary outcome measure (≥20 percent improvement in fatigue visual analog scale), compared with placebo [<a href="#rid90">90</a>]. Both the drug and placebo groups showed improvement, which could be attributed to glucocorticoid usage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Open-label trials</strong> – Open-label trials that each included small numbers of patients have been conducted with administration of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> either alone or in comparison with conventional DMARDs. Modest improvements in salivary gland function and patient-reported symptoms of fatigue, quality of life, and dryness were observed, but only in patients with residual salivary gland function [<a href="#rid87">87,95-97</a>]. The ESSDAI also decreased, mainly due to improvements in constitutional, glandular, hematologic, and biologic domains [<a href="#rid88">88,98</a>].</p><p></p><p class="bulletIndent1">In a prospective, two-center follow-up study of 41 patients with early active SjD, unstimulated saliva flow rates significantly improved at 120 weeks in the 19 patients who received <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> treatments every 24 weeks, compared with the 22 patients who received conventional DMARD therapy [<a href="#rid98">98</a>]. There was also a significant decrease in labial salivary gland lymphocytic infiltration (as measured by focus score) in the rituximab-treated patients. These findings need to be reproduced in a randomized trial but suggest that prolonged therapy with rituximab in early active disease is needed to realize significant clinical benefit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Retrospective case series and registry analyses</strong> – Parotid swelling, arthritis/arthralgias, cryoglobulinemic vasculitis, peripheral neuropathy, and scleritis have been treated successfully with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in a number of observational studies [<a href="#rid99">99-106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety of </strong><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a><strong> in Sjögren's syndrome</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Several reports have included a small number of patients who experienced adverse effects of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> therapy for extraglandular SjD, including serum-sickness-like reactions [<a href="#rid107">107,108</a>], infusion reactions [<a href="#rid89">89</a>], and interstitial lung disease [<a href="#rid109">109</a>]. In other conditions, such as SLE treated with rituximab, progressive multifocal encephalopathy has been reported [<a href="#rid110">110,111</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The use of <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 100 mg as a premedication before IV <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> infusion is associated with a low risk of infusion or serum-sickness-like reactions [<a href="#rid87">87,89-91</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In our experience, a slower rate of infusion is preferred, particularly during the initial infusions (over three to four hours), although the rate may be increased during subsequent infusions if there are no infusion reactions [<a href="#rid112">112</a>].</p><p></p><p class="headingAnchor" id="H858553139"><span class="h2">Other biologic agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor necrosis factor inhibitors</strong> – Several small studies and randomized trials of both <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> failed to demonstrate benefit in patients with SjD [<a href="#rid113">113-115</a>]. In one randomized trial involving 103 patients who received infliximab or placebo, there were no significant differences in the change from baseline in pain, fatigue, or sicca symptoms or in objective measures of salivary flow, swollen joints, tender joints, erythrocyte sedimentation rate (ESR), or C-reactive protein (CRP) [<a href="#rid113">113</a>]. Similarly, no benefit was seen in a trial involving 28 patients who were randomly assigned to receive either etanercept or placebo, despite a 19 percent decrease in the ESR over the 12-week study in the etanercept group [<a href="#rid115">115</a>]. A previous study, which had reported benefit from treatment with infliximab, was subsequently retracted [<a href="#rid116">116-118</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">Belimumab</a> – Belimumab, a monoclonal antibody directed against B-cell activating factor, was evaluated in an open-label trial of 30 primary SjD patients, which found a modest reduction in symptoms of dryness but not in fatigue at 28 and 52 weeks [<a href="#rid119">119,120</a>]. Saliva flow, Schirmer testing, and salivary biopsy focus score results did not change. However, there was improvement in nonmalignant parotid enlargement, arthritis/arthralgia, and in B-cell biomarker values, including serum immunoglobulin and RF levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">Abatacept</a> – Abatacept, a T cell costimulation blocker approved for the treatment of RA, showed promising results in two small open-label studies [<a href="#rid121">121,122</a>]. However, it was not more efficacious than placebo in the treatment of moderate to severe primary SjD in two large randomized trials. The first was a single-center study of 80 patients in which treatment with subcutaneous abatacept (125 mg each week) was associated with a greater improvement than placebo in systemic disease activity (as measured by the ESSDAI) at week 12, but not at week 24, the primary outcome measure [<a href="#rid123">123</a>]. The second study was a global, multicenter randomized trial of 187 patients. There was no statistically significant difference between abatacept and placebo in terms of change in ESSDAI or patient-reported severity of pain, fatigue, or dryness (using the EULAR SjD Patient-Reported Index [ESSPRI] scale) at day 169 [<a href="#rid124">124</a>]. In both trials, there was evidence of biologic activity of abatacept, but a robust placebo response may have obscured evidence of clinical efficacy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">Tocilizumab</a> – Tocilizumab, an interleukin 6 (IL-6) receptor inhibitor, was assessed for clinical benefit in primary SjD in a multicenter randomized trial involving 110 patients and lasting 24 weeks. Tocilizumab treatment, relative to placebo, was not associated with any greater improvement in systemic involvement and symptoms [<a href="#rid125">125</a>].</p><p></p><p class="headingAnchor" id="H3544304404"><span class="h2">Other agents in clinical trials</span><span class="headingEndMark"> — </span>A number of other therapeutic approaches have been tried or are under investigation in SjD. In randomized placebo-controlled clinical trials, the primary outcome of a significant reduction in systemic disease activity (as measured by the ESSDAI) was achieved for remibrutinib (a Bruton tyrosine kinase inhibitor) [<a href="#rid126">126</a>], low-dose IL-2 [<a href="#rid127">127</a>]; ianalumab (BAFF receptor inhibitor and B-cell depleter) [<a href="#rid128">128</a>], iscalimab (CD40 blockade) [<a href="#rid129">129</a>], telitacicept (BAFF and APRIL inhibitor) [<a href="#rid130">130</a>], and dazodalibep (CD40 ligand antagonist) [<a href="#rid131">131</a>]. These positive results await verification in larger phase 3 trials. Further clinical testing was not pursued due to side effects or inefficacy for <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, oromucosal interferon alfa [<a href="#rid132">132</a>], <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> [<a href="#rid133">133</a>], baminercept [<a href="#rid134">134</a>], seletalisib [<a href="#rid135">135</a>], prezalumab [<a href="#rid136">136</a>], petesicatib [<a href="#rid137">137</a>], and efalizumab [<a href="#rid138">138</a>]. Information concerning ongoing trials in the United States can be found at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=113735" target="_blank">www.clinicaltrials.gov</a>.</p><p class="headingAnchor" id="H635765594"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117117.html" rel="external">"Society guideline links: Sjögren's disease"</a>.)</p><p class="headingAnchor" id="H577092689"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/580.html" rel="external">"Patient education: Sjögren's disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H490759739"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overall approach</strong> – Evaluation and management of Sjögren's disease (SjD) should be provided by a multidisciplinary team. Patients should undergo a thorough pretreatment evaluation to confirm the diagnosis and determine the severity and extent of disease and the disease subset. The approach to management is generally the same for primary or secondary SjD. (See <a class="local">'Treatment goals and principles'</a> above and <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpharmacologic interventions</strong> – All patients should receive nonpharmacologic and preventive interventions, including patient education regarding self-care measures and the benefits of smoking cessation, counseling regarding diet and medication use, routine preventive care and immunizations, and pregnancy counseling. (See <a class="local">'Nonpharmacologic and preventive interventions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sicca management</strong> – In patients with mild SjD, which includes those with sicca symptoms alone, without glandular enlargement or other organ involvement, treatment generally does not require systemic therapy other than secretagogues, in addition to local treatment for ocular, oral, and other symptoms of dryness, monitoring of the condition, and usual medical and dental preventive care. (See  <a class="medical medical_review" href="/z/d/html/14922.html" rel="external">"Treatment of dry eye in Sjögren’s disease: General principles and initial therapy"</a> and  <a class="medical medical_review" href="/z/d/html/14923.html" rel="external">"Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to other disease manifestations</strong> – Management of patients with moderate to severe involvement depends on the clinical manifestation, tissues, and organ system affected, and may involve systemic medical therapy, including the use of immunosuppressives and biologic agents. Treatment has been influenced by the approach for other systemic rheumatic diseases, particularly systemic lupus erythematosus (SLE) as well as rheumatoid arthritis (RA). (See <a class="local">'Approach to drug therapy'</a> above and <a class="local">'Therapy for organ-based disease and constitutional symptoms'</a> above and <a class="local">'Therapeutic rationale and evidence overview'</a> above and <a class="local">'Efficacy of specific therapeutic agents'</a> above.)</p><p></p><p class="bulletIndent1">We generally use the following approach:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Salivary gland enlargement</strong> – Symptomatic treatment may be sufficient for some patients with salivary gland enlargement, particularly those with acute unilateral involvement. For patients with major salivary glandular enlargement who have an inadequate response to symptomatic management, we suggest a short course of glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A typical regimen is <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 20 mg/day for one week followed by a gradual taper to finish a two-week course. Patients with recurrent obstructive symptoms related to sialolithiasis or sialostenosis can be managed prophylactically with secretagogues. Patients with acute salivary gland swelling and fevers due to bacterial sialadenitis require broad-spectrum antibiotics. Recurrent episodes of glucocorticoid-responsive autoimmune sialadenitis can be prevented with the use of <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. Patients with major salivary gland swelling that persists for more than 12 weeks despite therapy should undergo evaluation for malignancy, especially when the gland feels indurated, nodular, or is associated with regional adenopathy. (See <a class="local">'Salivary gland enlargement'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Musculoskeletal pain</strong> – In patients with mild joint symptoms, including mild arthritis and/or arthralgia and myalgia, we suggest nonsteroidal antiinflammatory drugs (NSAIDs) in antiinflammatory doses given daily or as needed depending upon symptom frequency (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with an inadequate response to NSAIDs or with moderate to severe symptoms, we suggest a traditional nonbiologic disease-modifying antirheumatic drug (DMARD), such as <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> or low-dose weekly <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> in doses typically used for RA (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Fibromyalgia is treated in the same fashion as in patients without SjD except that we attempt to minimize the use of agents with strong anticholinergic properties. (See <a class="local">'Musculoskeletal pain'</a> above and  <a class="medical medical_review" href="/z/d/html/5627.html" rel="external">"Treatment of fibromyalgia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/118590.html" rel="external">"Overview of chronic widespread (centralized) pain in the rheumatic diseases", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fatigue</strong> – In patients with fatigue that is largely related to the SjD itself, we treat initially with a low-impact aerobic exercise program and energy conservation measures. In patients with fatigue refractory to exercise and other lifestyle changes, we suggest <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> in a fashion similar to the approach utilized for SLE, rather than glucocorticoids or a DMARD (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Other comorbidities that can cause fatigue in SjD patients should be identified and treated separately. (See <a class="local">'Fatigue'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cutaneous manifestations</strong> – Treatment of cutaneous manifestations of SjD varies by the condition. Pruritus is largely managed symptomatically. Annular erythema is treated initially with topical steroids or topical calcineurin inhibitors, or with oral glucocorticoids (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 5 to 30 mg/day) for more severe or widespread disease; for recurrent skin lesions, we use systemic therapies that have benefit in cutaneous lupus, such as <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> or low-dose weekly <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. Treatment of cutaneous vasculitis depends upon the cause and whether an associated illness is present and may include local measures, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, glucocorticoids, or nonbiologic or biologic DMARDs. (See <a class="local">'Pruritus'</a> above and <a class="local">'Annular erythema'</a> above and <a class="local">'Cutaneous vasculitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Raynaud phenomenon</strong> – Raynaud phenomenon is treated as it is in other rheumatic diseases. (See <a class="local">'Raynaud phenomenon'</a> above and  <a class="medical medical_review" href="/z/d/html/7540.html" rel="external">"Treatment of Raynaud phenomenon: Initial management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiopulmonary disease</strong> – The treatment of most cardiopulmonary manifestations, including interstitial lung disease, pulmonary hypertension, and pleuropericarditis, is approached in the same way as in patients with other systemic rheumatic disorders, such as SLE or systemic sclerosis. (See <a class="local">'Cardiopulmonary manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Renal disease</strong> – The management of interstitial nephritis (IN) with renal tubular acidosis (RTA) and glomerulonephritis (GN) are described separately. The treatment of thrombotic glomerulopathy caused by antiphospholipid syndrome (APS) in SjD is the same as for patients with SLE. (See  <a class="medical medical_review" href="/z/d/html/7187.html" rel="external">"Kidney disease in primary Sjögren's disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrointestinal disorders</strong> – Treatment of any of the various gastrointestinal disorders associated with SjD requires a careful diagnostic evaluation and appropriate therapeutic interventions for the primary disorder (eg, gastroesophageal reflux or dysmotility) and for aspects of the SjD that may be contributing to the disorder (eg, treatment with secretagogues to improve salivary flow). Associated conditions (eg, celiac disease or primary biliary cholangitis [cirrhosis]) should be identified and treated as in patients without SjD. (See <a class="local">'Gastrointestinal'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurologic manifestations</strong> – The treatment of neurologic manifestations differs depending upon the specific involvement. (See <a class="local">'Neurologic manifestations'</a> above and  <a class="medical medical_review" href="/z/d/html/120953.html" rel="external">"Neurologic manifestations of Sjögren's disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hematologic abnormalities</strong> – Hematologic manifestations include cytopenias, monoclonal gammopathies, and non-Hodgkin B-cell lymphoma. (See <a class="local">'Hematologic'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The majority of patients with leukopenia do not require specific therapy. Specific intervention (which may include glucocorticoids, intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), or granulocyte-stimulating factors) is reserved for patients with severe infections or those requiring surgery. (See <a class="local">'Cytopenias'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Severe immune thrombocytopenia is treated as in other rheumatic diseases. (See  <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We evaluate monoclonal proteins according to guidelines recommended for monoclonal gammopathy of undetermined significance and monitor relevant laboratory studies on an annual basis unless specific symptoms arise suggesting the development of a hematologic malignancy. (See <a class="local">'Monoclonal gammopathy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The treatment of lymphomas seen in patients with SjD uses the same regimens as in patients without SjD, although the management of extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) in SjD involves unique considerations. (See <a class="local">'Lymphoma'</a> above.)</p><p></p><p class="headingAnchor" id="H2187016062"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Creamer, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis 2020; 79:3.</a></li><li><a class="nounderline abstract_t">Carsons SE, Vivino FB, Parke A, et al. Treatment guidelines for rheumatologic manifestations of Sjögren's syndrome: Use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken) 2017; 69:517.</a></li><li><a class="nounderline abstract_t">Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome. Rheumatology (Oxford) 2017; 56:e24.</a></li><li><a class="nounderline abstract_t">Sumida T, Azuma N, Moriyama M, et al. Clinical practice guideline for Sjögren's syndrome 2017. Mod Rheumatol 2018; 28:383.</a></li><li><a class="nounderline abstract_t">Devauchelle-Pensec V, Mariette X, Benyoussef AA, et al. French national diagnostic and care protocol for Sjögren's disease. Rev Med Interne 2023; 44:423.</a></li><li><a class="nounderline abstract_t">Mandel L. Salivary gland disorders. Med Clin North Am 2014; 98:1407.</a></li><li><a class="nounderline abstract_t">Wang S, Marchal F, Zou Z, et al. Classification and management of chronic sialadenitis of the parotid gland. J Oral Rehabil 2009; 36:2.</a></li><li><a class="nounderline abstract_t">Venables PJ. Management of patients presenting with Sjogren's syndrome. Best Pract Res Clin Rheumatol 2006; 20:791.</a></li><li><a class="nounderline abstract_t">Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjoegren's syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore) 1965; 44:187.</a></li><li><a class="nounderline abstract_t">Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013; 72:1026.</a></li><li><a class="nounderline abstract_t">Randell RL, Stern SM, Van Mater H, et al. Pediatric rheumatologists' perspectives on diagnosis, treatment, and outcomes of Sjögren disease in children and adolescents. Pediatr Rheumatol Online J 2022; 20:79.</a></li><li><a class="nounderline abstract_t">De Vita S, Isola M, Baldini C, et al. Predicting lymphoma in Sjögren's syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording. Rheumatology (Oxford) 2023; 62:1586.</a></li><li><a class="nounderline abstract_t">Kuan EC, Mallen-St Clair J, St John MA. Evaluation of Parotid Lesions. Otolaryngol Clin North Am 2016; 49:313.</a></li><li><a class="nounderline abstract_t">Baer AN, Grader-Beck T, Antiochos B, et al. Ultrasound-Guided Biopsy of Suspected Salivary Gland Lymphoma in Sjögren's Syndrome. Arthritis Care Res (Hoboken) 2021; 73:849.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, et al. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol 2012; 8:399.</a></li><li><a class="nounderline abstract_t">Thanou-Stavraki A, James JA. Primary Sjogren's syndrome: current and prospective therapies. Semin Arthritis Rheum 2008; 37:273.</a></li><li><a class="nounderline abstract_t">Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20.</a></li><li><a class="nounderline abstract_t">Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324:150.</a></li><li><a class="nounderline abstract_t">Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996; 5 Suppl 1:S31.</a></li><li><a class="nounderline abstract_t">Kruize AA, Hené RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993; 52:360.</a></li><li><a class="nounderline abstract_t">Gudbjörnsson B, Broman JE, Hetta J, Hällgren R. Sleep disturbances in patients with primary Sjögren's syndrome. Br J Rheumatol 1993; 32:1072.</a></li><li><a class="nounderline abstract_t">Usmani ZA, Hlavac M, Rischmueller M, et al. Sleep disordered breathing in patients with primary Sjögren's syndrome: a group controlled study. Sleep Med 2012; 13:1066.</a></li><li><a class="nounderline abstract_t">Santos EJF, Farisogullari B, Dures E, et al. Efficacy of non-pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. RMD Open 2023; 9.</a></li><li><a class="nounderline abstract_t">Kim HJ. Pruritus in autoimmune connective tissue diseases. Ann Transl Med 2021; 9:441.</a></li><li><a class="nounderline abstract_t">Dipalma JR. Tartrazine sensitivity. Am Fam Physician 1990; 42:1347.</a></li><li><a class="nounderline abstract_t">Stenius BS, Lemola M. Hypersensitivity to acetylsalicylic acid (ASA) and tartrazine in patients with asthma. Clin Allergy 1976; 6:119.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Brito-Zerón P, Seror R, et al. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford) 2015; 54:2230.</a></li><li><a class="nounderline abstract_t">Katayama I, Kotobuki Y, Kiyohara E, Murota H. Annular erythema associated with Sjögren's syndrome: review of the literature on the management and clinical analysis of skin lesions. Mod Rheumatol 2010; 20:123.</a></li><li><a class="nounderline abstract_t">Yokota K, Shichinohe R, Hayasaka T. Topical tacrolimus in the treatment of annular erythema associated with Sjögren's syndrome. Clin Exp Dermatol 2005; 30:450.</a></li><li><a class="nounderline abstract_t">Nobeyama Y, Matsuzaki H, Nakagawa H. Annular erythema of Sjögren's syndrome treated successfully with low-dose cyclosporine. J Dermatol 2014; 41:463.</a></li><li><a class="nounderline abstract_t">Privette ED, Werth VP. Update on pathogenesis and treatment of CLE. Curr Opin Rheumatol 2013; 25:584.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Anaya JM, García-Carrasco M, et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) 2004; 83:96.</a></li><li><a class="nounderline abstract_t">Quartuccio L, Isola M, Baldini C, et al. Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study. Scand J Rheumatol 2015; 44:36.</a></li><li><a class="nounderline abstract_t">Finder KA, McCollough ML, Dixon SL, et al. Hypergammaglobulinemic purpura of Waldenström. J Am Acad Dermatol 1990; 23:669.</a></li><li><a class="nounderline abstract_t">Ferreiro JE, Pasarin G, Quesada R, Gould E. Benign hypergammaglobulinemic purpura of Waldenström associated with Sjögren's syndrome. Case report and review of immunologic aspects. Am J Med 1986; 81:734.</a></li><li><a class="nounderline abstract_t">Mathis J, Zirwas M, Elkins CT, et al. JAAD grand rounds. Persistent and progressive purpura in a patient with an elevated rheumatoid factor and polyclonal gammopathy (hypergammaglobulinemic purpura of Waldenström). J Am Acad Dermatol 2015; 72:374.</a></li><li><a class="nounderline abstract_t">Habib GS, Nashashibi M. Hypergammaglobulinemic purpura in two sisters with Sjogren's syndrome responding to colchicine treatment. Clin Rheumatol 2004; 23:170.</a></li><li><a class="nounderline abstract_t">Shahin AA, El-Agha S, El-Azkalany GS. The effect of leflunomide on the eye dryness in secondary Sjögren's syndrome associated with rheumatoid arthritis and in rheumatoid arthritis patients. Clin Rheumatol 2014; 33:925.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet 2012; 379:348.</a></li><li><a class="nounderline abstract_t">Lee AS, Scofield RH, Hammitt KM, et al. Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's. Chest 2021; 159:683.</a></li><li><a class="nounderline abstract_t">Kreider M, Highland K. Pulmonary involvement in Sjögren syndrome. Semin Respir Crit Care Med 2014; 35:255.</a></li><li><a class="nounderline abstract_t">Andres E, Serraj K. Optimal management of pernicious anemia. J Blood Med 2012; 3:97.</a></li><li><a class="nounderline abstract_t">Szodoray P, Barta Z, Lakos G, et al. Coeliac disease in Sjögren's syndrome--a study of 111 Hungarian patients. Rheumatol Int 2004; 24:278.</a></li><li><a class="nounderline abstract_t">Selmi C, Meroni PL, Gershwin ME. Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis. J Autoimmun 2012; 39:34.</a></li><li><a class="nounderline abstract_t">Sun Y, Zhang W, Li B, et al. The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review. Clin Rev Allergy Immunol 2015; 48:301.</a></li><li><a class="nounderline abstract_t">Krogh K, Asmussen K, Stengaard-Pedersen K, et al. Bowel symptoms in patients with primary Sjögren's syndrome. Scand J Rheumatol 2007; 36:407.</a></li><li><a class="nounderline abstract_t">Park T, Cave D, Marshall C. Microscopic colitis: A review of etiology, treatment and refractory disease. World J Gastroenterol 2015; 21:8804.</a></li><li><a class="nounderline abstract_t">Manganelli P, Fietta P, Quaini F. Hematologic manifestations of primary Sjögren's syndrome. Clin Exp Rheumatol 2006; 24:438.</a></li><li><a class="nounderline abstract_t">Brito-Zerón P, Ramos-Casals M. [Prognosis of patients with primary Sjögren's syndrome]. Med Clin (Barc) 2008; 130:109.</a></li><li><a class="nounderline abstract_t">Coppo P, Sibilia J, Maloisel F, et al. Primary Sjögren's syndrome associated agranulocytosis: a benign disorder? Ann Rheum Dis 2003; 62:476.</a></li><li><a class="nounderline abstract_t">Fialho SC, Bergamaschi S, Neves FS, et al. Mycophenolate mofetil in primary Sjögren's syndrome: a treatment option for agranulocytosis. Rev Bras Reumatol 2012; 52:297.</a></li><li><a class="nounderline abstract_t">Gorodetskiy V, Vasilyev V, Sidorova Y, et al. Clinical Study of the Relationship between Sjögren Syndrome and T-Cell Large Granular Lymphocytic Leukemia: Single-Center Experience. Int J Mol Sci 2022; 23.</a></li><li><a class="nounderline abstract_t">Warren JS. Clinically unsuspected cryoglobulinemia: cases that present as laboratory artifact. Am J Clin Pathol 2013; 139:352.</a></li><li class="breakAll">Baer AN, Ambinder RF. Lymphoproliferative disease in Sjögren’s syndrome. In: Sjögren’s Syndrome: A Clinical Handbook, Vivino FB (Ed), Elsevier, Amsterdam 2019. p.129.</li><li><a class="nounderline abstract_t">Voulgarelis M, Ziakas PD, Papageorgiou A, et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore) 2012; 91:1.</a></li><li><a class="nounderline abstract_t">Pollard RP, Pijpe J, Bootsma H, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study. J Rheumatol 2011; 38:2198.</a></li><li><a class="nounderline abstract_t">Brito-Zerón P, Ramos-Casals M, EULAR-SS task force group. Advances in the understanding and treatment of systemic complications in Sjögren's syndrome. Curr Opin Rheumatol 2014; 26:520.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010; 304:452.</a></li><li><a class="nounderline abstract_t">Fazaa A, Bourcier T, Chatelus E, et al. Classification criteria and treatment modalities in primary Sjögren's syndrome. Expert Rev Clin Immunol 2014; 10:543.</a></li><li><a class="nounderline abstract_t">Vivino FB, Carsons SE, Foulks G, et al. New Treatment Guidelines for Sjögren's Disease. Rheum Dis Clin North Am 2016; 42:531.</a></li><li><a class="nounderline abstract_t">Foulks GN, Forstot SL, Donshik PC, et al. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf 2015; 13:118.</a></li><li><a class="nounderline abstract_t">Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjögren syndrome. Nat Rev Rheumatol 2016; 12:456.</a></li><li><a class="nounderline abstract_t">Devauchelle-Pensec V, Gottenberg JE, Jousse-Joulin S, et al. Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome? PLoS One 2015; 10:e0133907.</a></li><li><a class="nounderline abstract_t">Seror R, Theander E, Bootsma H, et al. Outcome measures for primary Sjögren's syndrome: a comprehensive review. J Autoimmun 2014; 51:51.</a></li><li><a class="nounderline abstract_t">Vissink A, Bootsma H, Kroese FG, Kallenberg CG. How to assess treatment efficacy in Sjögren's syndrome? Curr Opin Rheumatol 2012; 24:281.</a></li><li><a class="nounderline abstract_t">Felten R, Scher F, Sibilia J, et al. The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials. Autoimmun Rev 2019; 18:576.</a></li><li><a class="nounderline abstract_t">Gandolfo S, De Vita S. Emerging drugs for primary Sjögren's syndrome. Expert Opin Emerg Drugs 2019; 24:121.</a></li><li><a class="nounderline abstract_t">Fox PC, Datiles M, Atkinson JC, et al. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol 1993; 11:149.</a></li><li><a class="nounderline abstract_t">Miyawaki S, Nishiyama S, Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. Intern Med 1999; 38:938.</a></li><li><a class="nounderline abstract_t">Hernandez YL, Daniels TE. Oral candidiasis in Sjögren's syndrome: prevalence, clinical correlations, and treatment. Oral Surg Oral Med Oral Pathol 1989; 68:324.</a></li><li><a class="nounderline abstract_t">Gheitasi H, Kostov B, Solans R, et al. How are we treating our systemic patients with primary Sjögren syndrome? Analysis of 1120 patients. Int Immunopharmacol 2015; 27:194.</a></li><li><a class="nounderline abstract_t">Fox RI, Chan E, Benton L, et al. Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med 1988; 85:62.</a></li><li><a class="nounderline abstract_t">Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 1999; 58:253.</a></li><li><a class="nounderline abstract_t">Fauchais AL, Ouattara B, Gondran G, et al. Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford) 2010; 49:1164.</a></li><li><a class="nounderline abstract_t">Koh JH, Park Y, Lee J, et al. Hypergammaglobulinaemia predicts glandular and extra-glandular damage in primary Sjögren's syndrome: results from the KISS cohort study. Clin Exp Rheumatol 2021; 39 Suppl 133:114.</a></li><li><a class="nounderline abstract_t">Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 2014; 312:249.</a></li><li><a class="nounderline abstract_t">Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol 1996; 14:555.</a></li><li><a class="nounderline abstract_t">Price EJ, Rigby SP, Clancy U, Venables PJ. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. J Rheumatol 1998; 25:896.</a></li><li><a class="nounderline abstract_t">van Woerkom JM, Kruize AA, Geenen R, et al. Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study. Ann Rheum Dis 2007; 66:1026.</a></li><li><a class="nounderline abstract_t">van der Heijden EHM, Blokland SLM, Hillen MR, et al. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. Lancet Rheumatol 2020; 2:e260.</a></li><li><a class="nounderline abstract_t">Willeke P, Schlüter B, Becker H, et al. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. Arthritis Res Ther 2007; 9:R115.</a></li><li><a class="nounderline abstract_t">Pereira PR, Viala K, Maisonobe T, et al. Sjögren Sensory Neuronopathy (Sjögren Ganglionopathy): Long-Term Outcome and Treatment Response in a Series of 13 Cases. Medicine (Baltimore) 2016; 95:e3632.</a></li><li><a class="nounderline abstract_t">Drosos AA, Skopouli FN, Costopoulos JS, et al. Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study. Ann Rheum Dis 1986; 45:732.</a></li><li><a class="nounderline abstract_t">Drosos AA, Skopouli FN, Galanopoulou VK, et al. Cyclosporin a therapy in patients with primary Sjögren's syndrome: results at one year. Scand J Rheumatol Suppl 1986; 61:246.</a></li><li><a class="nounderline abstract_t">Kedor C, Hagemann A, Zernicke J, et al. Effectiveness and safety of low-dose cyclosporine A in patients with primary Sjögren's syndrome (PSS) with articular involvement - results of a pilot study. Ann Rheum Dis 2015; 74:341.</a></li><li><a class="nounderline abstract_t">Looney RJ. Will targeting B cells be the answer for Sjögren's syndrome? Arthritis Rheum 2007; 56:1371.</a></li><li><a class="nounderline abstract_t">St Clair EW, Levesque MC, Prak ET, et al. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum 2013; 65:1097.</a></li><li><a class="nounderline abstract_t">Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis 2012; 71:1297.</a></li><li><a class="nounderline abstract_t">Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014; 160:233.</a></li><li><a class="nounderline abstract_t">Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67:1541.</a></li><li><a class="nounderline abstract_t">Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:960.</a></li><li><a class="nounderline abstract_t">Faustman DL, Vivino FB, Carsons SE. Treatment of primary Sjögren syndrome with rituximab. Ann Intern Med 2014; 161:376.</a></li><li class="breakAll">Bowman S, Everett C, Bombardieri M, et al. Preliminary results of a double-blind randomised trial of rituximab anti-b-cell therapy in patients with primary Sjogren's syndrome. Meeting abstracts, American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting, San Francisco, CA, November 2015.</li><li><a class="nounderline abstract_t">Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. Arthritis Rheumatol 2017; 69:1440.</a></li><li><a class="nounderline abstract_t">Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52:2740.</a></li><li><a class="nounderline abstract_t">Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57:310.</a></li><li><a class="nounderline abstract_t">Devauchelle-Pensec V, Morvan J, Rat AC, et al. Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2011; 29:6.</a></li><li><a class="nounderline abstract_t">Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 2013; 15:R172.</a></li><li><a class="nounderline abstract_t">Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 2012; 71:84.</a></li><li><a class="nounderline abstract_t">Bryce AH, Dispenzieri A, Kyle RA, et al. Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma 2006; 7:140.</a></li><li><a class="nounderline abstract_t">Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64:913.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, García-Hernández FJ, de Ramón E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010; 28:468.</a></li><li><a class="nounderline abstract_t">Ahmadi-Simab K, Lamprecht P, Nölle B, et al. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 2005; 64:1087.</a></li><li><a class="nounderline abstract_t">Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken) 2010; 62:1787.</a></li><li><a class="nounderline abstract_t">Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007; 35:66.</a></li><li><a class="nounderline abstract_t">Botez SA, Herrmann DN. Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sjögren's syndrome after Rituximab therapy. J Clin Neuromuscul Dis 2010; 11:127.</a></li><li><a class="nounderline abstract_t">Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007; 66:351.</a></li><li><a class="nounderline abstract_t">Todd DJ, Helfgott SM. Serum sickness following treatment with rituximab. J Rheumatol 2007; 34:430.</a></li><li><a class="nounderline abstract_t">Hadjinicolaou AV, Nisar MK, Parfrey H, et al. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 2012; 51:653.</a></li><li><a class="nounderline abstract_t">Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9:425.</a></li><li><a class="nounderline abstract_t">Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834.</a></li><li><a class="nounderline abstract_t">Pritchard CH, Greenwald MW, Kremer JM, et al. Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study. BMC Musculoskelet Disord 2014; 15:177.</a></li><li><a class="nounderline abstract_t">Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50:1270.</a></li><li><a class="nounderline abstract_t">Zandbelt MM, de Wilde P, van Damme P, et al. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol 2004; 31:96.</a></li><li><a class="nounderline abstract_t">Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004; 50:2240.</a></li><li><a class="nounderline abstract_t">Steinfeld SD, Demols P, Salmon I, et al. Notice of retraction of two articles (“Infliximab in patients with primary Sjögren’s syndrome: a pilot study” and “Infliximab in patients with primary Sjögren’s syndrome: one-year followup”). Arthritis Rheum 2013; 65:814.</a></li><li><a class="nounderline abstract_t">Steinfeld SD, Demols P, Salmon I, et al. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum 2001; 44:2371.</a></li><li><a class="nounderline abstract_t">Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjögren's syndrome: one-year followup. Arthritis Rheum 2002; 46:3301.</a></li><li><a class="nounderline abstract_t">De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study. Rheumatology (Oxford) 2015; 54:2249.</a></li><li><a class="nounderline abstract_t">Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2015; 74:526.</a></li><li><a class="nounderline abstract_t">Adler S, Körner M, Förger F, et al. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren’s syndrome: a pilot study. Arthritis Care Res (Hoboken) 2013; 65:1862.</a></li><li><a class="nounderline abstract_t">Meiners PM, Vissink A, Kroese FG, et al. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 2014; 73:1393.</a></li><li><a class="nounderline abstract_t">van Nimwegen JF, Mossel E, van Zuiden GS, et al. Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). Lancet Rheumatol 2020; 2:e153.</a></li><li><a class="nounderline abstract_t">Baer AN, Gottenberg JE, St Clair EW, et al. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial. Ann Rheum Dis 2021; 80:339.</a></li><li><a class="nounderline abstract_t">Felten R, Devauchelle-Pensec V, Seror R, et al. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis 2021; 80:329.</a></li><li><a class="nounderline abstract_t">Dörner T, Kaul M, Szántó A, et al. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Ann Rheum Dis 2023.</a></li><li><a class="nounderline abstract_t">He J, Chen J, Miao M, et al. Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial. JAMA Netw Open 2022; 5:e2241451.</a></li><li><a class="nounderline abstract_t">Bowman SJ, Fox R, Dörner T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 2022; 399:161.</a></li><li><a class="nounderline abstract_t">Fisher BA, Szanto A, Ng WF, et al. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. Lancet Rheumatol 2020; 2:e142.</a></li><li><a class="nounderline abstract_t">Xu D, Fang J, Zhang S, et al. Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology (Oxford) 2023.</a></li><li><a class="nounderline abstract_t">St. Clair E, Wang L, Alevizos I, et al. Efficacy and safety of dazodalibep (VIB 4920/HZN4920) in subjects with Sjögren’s syndrome: A phase 2, randomized,double-blind, placebo-controlled, proof of concept study. Ann Rheum Dis 2023; 82:95.</a></li><li><a class="nounderline abstract_t">Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003; 49:585.</a></li><li><a class="nounderline abstract_t">Norheim KB, Harboe E, Gøransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial. PLoS One 2012; 7:e30123.</a></li><li><a class="nounderline abstract_t">St Clair EW, Baer AN, Wei C, et al. Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 2018; 70:1470.</a></li><li><a class="nounderline abstract_t">Juarez M, Diaz N, Johnston GI, et al. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. Rheumatology (Oxford) 2021; 60:1364.</a></li><li class="breakAll">Mariette X, Bombardieri M, Alevizos I, et al. A Phase 2A study of MEDI5872 (AMG557), a fully human anti-ICOS ligand monoclonal antibody in patients with primary Sjögren’s syndrome. Abstract, American College of Rheumatology/Association of Rheumatologist Professionals Annual Meeting, Atlanta, United States, November 2019.</li><li><a class="nounderline abstract_t">Bentley D, Fisher BA, Barone F, et al. A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome. Rheumatology (Oxford) 2023; 62:3644.</a></li><li><a class="nounderline abstract_t">Tran D, Bebris L, Shevach E, Illei G. Efalizumab down-regulates CD25 expression on FOXP3+ regulatory T cells and exacerbates the autoimmunity in primary Sjogren’s syndrome. J Immunol 2010; 184:96.4.</a></li></ol></div><div id="topicVersionRevision">Topic 113735 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672775" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27390247" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment guidelines for rheumatologic manifestations of Sjögren's syndrome: Use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28957550" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29409370" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical practice guideline for Sjögren's syndrome 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37453854" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : French national diagnostic and care protocol for Sjögren's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25443682" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Salivary gland disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18976271" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Classification and management of chronic sialadenitis of the parotid gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16979538" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Management of patients presenting with Sjogren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14315274" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sjoegren's syndrome. A clinical, pathological, and serological study of sixty-two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23264337" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36064423" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pediatric rheumatologists' perspectives on diagnosis, treatment, and outcomes of Sjögren disease in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36063040" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Predicting lymphoma in Sjögren's syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26902978" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evaluation of Parotid Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32248649" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ultrasound-Guided Biopsy of Suspected Salivary Gland Lymphoma in Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22549247" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Topical and systemic medications for the treatment of primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17714766" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Primary Sjogren's syndrome: current and prospective therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19103632" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984192" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8803908" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8323383" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8252317" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sleep disturbances in patients with primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22841036" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sleep disordered breathing in patients with primary Sjögren's syndrome: a group controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37604639" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy of non-pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33842662" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pruritus in autoimmune connective tissue diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2239641" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tartrazine sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1277437" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hypersensitivity to acetylsalicylic acid (ASA) and tartrazine in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26231345" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20054701" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Annular erythema associated with Sjögren's syndrome: review of the literature on the management and clinical analysis of skin lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15953102" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Topical tacrolimus in the treatment of annular erythema associated with Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24801928" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Annular erythema of Sjögren's syndrome treated successfully with low-dose cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23872903" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Update on pathogenesis and treatment of CLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028963" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25268749" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2229494" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hypergammaglobulinemic purpura of Waldenström.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3766605" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Benign hypergammaglobulinemic purpura of Waldenström associated with Sjögren's syndrome. Case report and review of immunologic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25592359" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : JAAD grand rounds. Persistent and progressive purpura in a patient with an elevated rheumatoid factor and polyclonal gammopathy (hypergammaglobulinemic purpura of Waldenström).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15045635" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hypergammaglobulinemic purpura in two sisters with Sjogren's syndrome responding to colchicine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24647977" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The effect of leflunomide on the eye dryness in secondary Sjögren's syndrome associated with rheumatoid arthritis and in rheumatoid arthritis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868085" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The cryoglobulinaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33075377" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24668540" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pulmonary involvement in Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23028239" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Optimal management of pernicious anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13680146" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Coeliac disease in Sjögren's syndrome--a study of 111 Hungarian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22178199" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25682089" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17963176" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Bowel symptoms in patients with primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26269669" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Microscopic colitis: A review of etiology, treatment and refractory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16956437" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hematologic manifestations of primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18261383" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : [Prognosis of patients with primary Sjögren's syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12695164" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Primary Sjögren's syndrome associated agranulocytosis: a benign disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22460418" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Mycophenolate mofetil in primary Sjögren's syndrome: a treatment option for agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36362126" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical Study of the Relationship between Sjögren Syndrome and T-Cell Large Granular Lymphocytic Leukemia: Single-Center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23429372" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinically unsuspected cryoglobulinemia: cases that present as laboratory artifact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23429372" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinically unsuspected cryoglobulinemia: cases that present as laboratory artifact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22198497" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844152" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25050925" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Advances in the understanding and treatment of systemic complications in Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664046" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment of primary Sjögren syndrome: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24646087" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Classification criteria and treatment modalities in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27431353" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : New Treatment Guidelines for Sjögren's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25881996" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clinical guidelines for management of dry eye associated with Sjögren disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27411907" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of primary Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26368934" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24411404" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Outcome measures for primary Sjögren's syndrome: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22450393" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : How to assess treatment efficacy in Sjögren's syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30959220" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31286787" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Emerging drugs for primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8508556" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prednisone and piroxicam for treatment of primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10628930" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2788854" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Oral candidiasis in Sjögren's syndrome: prevalence, clinical correlations, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25899085" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : How are we treating our systemic patients with primary Sjögren syndrome? Analysis of 1120 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3177432" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Treatment of primary Sjögren's syndrome with hydroxychloroquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10364906" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20299380" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34796856" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hypergammaglobulinaemia predicts glandular and extra-glandular damage in primary Sjögren's syndrome: results from the KISS cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25027140" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8913659" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Methotrexate in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9598887" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223657" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38273473" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986340" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27175675" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Sjögren Sensory Neuronopathy (Sjögren Ganglionopathy): Long-Term Outcome and Treatment Response in a Series of 13 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3532967" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3296152" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cyclosporin a therapy in patients with primary Sjögren's syndrome: results at one year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effectiveness and safety of low-dose cyclosporine A in patients with primary Sjögren's syndrome (PSS) with articular involvement - results of a pilot study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17469093" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Will targeting B cells be the answer for Sjögren's syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23334994" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258489" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24727841" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Treatment of primary Sjögren syndrome with rituximab: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18276741" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20131246" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25178574" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Treatment of primary Sjögren syndrome with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25178574" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Treatment of primary Sjögren syndrome with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28296257" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16142737" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17330280" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21345287" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24286296" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21926185" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17026826" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Response to rituximab in patients with type II cryoglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15550531" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20525449" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15958765" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20740617" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16967492" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20215986" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sjögren's syndrome after Rituximab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950808" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17295433" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Serum sickness following treatment with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22157468" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Non-infectious pulmonary toxicity of rituximab: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20298966" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19264918" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24884454" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15077311" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14705226" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15248223" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23565525" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Notice of retraction of two articles (“Infliximab in patients with primary Sjögren’s syndrome: a pilot study”and“Infliximab in patients with primary Sjögren’s syndrome: one-year followup”).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11665979" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Infliximab in patients with primary Sjögren's syndrome: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12483735" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Infliximab in primary Sjögren's syndrome: one-year followup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26242856" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24347569" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23740889" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren’s syndrome: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24473674" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38263653" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33168545" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33208345" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37932009" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36355371" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34861168" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38263652" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37399108" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Efficacy and safety of dazodalibep (VIB 4920/HZN4920) in subjects with Sjögren’s syndrome: A phase 2, randomized,double-blind, placebo-controlled, proof of concept study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12910567" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22253903" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29604186" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Clinical Efficacy and Safety of Baminercept, a LymphotoxinβReceptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32949140" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32949140" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36864622" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Efalizumab down-regulates CD25 expression on FOXP3+ regulatory T cells and exacerbates the autoimmunity in primary Sjogren’s syndrome</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
